BZE-2209

N/A

Report date: 2024/02/28 20:04:05

Base Information

Drug NameBZE-2209
Drug Alias NameBZE-2209BZE2209αPD1/CTLA4-MSLN-CAR T Cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsImmunologic cytotoxicityProgrammed cell death protein 1 antagonists +[4] 
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Programmed cell death protein 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Cell Therapy Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Cell Therapy Group Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A